Topic
Heart and kidney
3 reports, newest first.
Semaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trial
In a 52-week randomised trial in type 2 diabetes and chronic kidney disease, semaglutide did not significantly alter the coprimary kidney MRI outcomes versus placebo. Some secondary imaging and tissue findings favoured it.
ADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabetes
The updated ADA and EASD consensus widens the focus from glucose control to holistic management and advocates earlier use, possibly from diagnosis, of SGLT2 inhibitors or GLP-1-based therapies.
Nearly one in four indigenous adults in Odisha had impaired kidney function in a survey
A secondary analysis of 19,703 indigenous adults in Odisha found impaired kidney function in 24.8%, and tested machine learning models to predict it from routine data.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.